Dr Mats Jerkeman, MD, completed his training in Clinical Oncology at Lund University, Sweden, where he is currently Professor in Clinical Oncology, and Head of Division of Oncology. His research focuses on the development of clinical trials in lymphoma, and in clinical epidemiology. He is Chairman of the Nordic Lymphoma Group, and Editor of the ESMO Guidelines of Lymphoma.
Abbvie, AstraZeneca, Celgene, Gilead, Incyte, Janssen and Roche.
A review paper ‘Follicular lymphoma: recent and emerging therapies, treatment strategies, and remaining unmet needs’ authored by LYMPHOMA CONNECT members